Alkyl sulfonates are direct-acting bacterial mutagens and are almost universally regarded by regulatory authorities to be potential impurities in drug substances presented as sulfonic acid salts, particularly if synthesized using an alcohol solvent. A detailed review of the available public domain data indicates that regulatory policy appears to be based on speculation, assumption, and assertion rather than actual evidence. Ester formation from a sulfonic acid in the presence of an alcohol is an extremely slow and thermodynamically unfavored reaction requiring strongly acidic conditions to produce even minimal conversion. Following addition of an equimolar amount of a sulfonic acid to a pharmaceutical base (the active), proton transfer to form an acid salt occurs instantaneously, thus neutralizing the acid and precluding any ester formation as a side reaction even if an alcoholic solvent is employed. Other possible routes to sulfonic acid ester formation by interaction of an alcohol with preformed sulfonic acid salt or via impurities in the sulfonic acid reagent can also be discounted based on mechanistic and experimental evidence. By contrast, C 1 −C 3 chloroalkanes are formed more rapidly in HCl/alcohol systems, but they can be readily purged from hydrochloride salts (if an excess of acid is used for synthesis) and are much weaker biological alkylators than alkyl sulfonates. Generic/compound-specific limits for alkyl sulfonates and considerably higher limits for chloroalkanes can be derived using the available toxicological data and provisions of the International Conference on Harmonization (ICH) M7 guideline. Since alkyl-sulfonate impurities can now be predicted with certainty to be absent at toxicologically significant levels, the current regulatory paradigm is no longer considered to be justified, thus removing the hypothetically based perception of potential risk associated with sulfonic acid salts.